Levofloxacino Aurovitas (Levofloxacin)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial DNA synthesis, leading to cell death. This mechanism provides broad‑spectrum activity against many Gram‑negative and Gram‑positive organisms.

The prescribed dose of Levofloxacino Aurovitas is set by the treating physician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Dosage adjustments may be required for patients with impaired kidney function or in special populations.

Safety data for levofloxacin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Levofloxacino Aurovitas. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Levofloxacino Aurovitas, as a levofloxacin formulation, offers once‑daily dosing and a broad spectrum that includes many resistant Gram‑negative and Gram‑positive pathogens. Compared with older fluoroquinolones, it has improved pharmacokinetics, higher tissue penetration, and a lower propensity for certain resistance mechanisms, making it a preferred option for severe infections.

Levofloxacino Aurovitas should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not store at ambient temperature, as stability may be compromised.

The product is supplied as a sterile intravenous solution. It is administered by slow IV infusion, typically over 30‑60 minutes, under aseptic conditions. Administration rate and duration are determined by the prescribing clinician based on the infection being treated and patient tolerance.

Serious adverse events include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for musculoskeletal pain, cardiac symptoms, and gastrointestinal changes, and the drug should be discontinued if severe reactions occur.

Levofloxacino Aurovitas is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. Caution is advised for individuals with a history of tendon disorders, uncontrolled arrhythmias, or severe renal impairment. Pregnant or breastfeeding women should only use it when clearly indicated and after risk‑benefit assessment.